Domestic Substitution Accelerates in MedTech: Brosmed Medical Secures Hundreds of Millions in Series D Funding and Files IPO Prospectus

Smart Medical Device Network NewsRecently, BrosMed Medical Co., Ltd. (hereinafter referred to as"BrosMed Medical" announced the completion of financing worth hundreds of millions. This round was led byIDGLed by Capital, followed by Sunshine Ronghui Capital, Mirae Asset, and Singularity Capital, with StarBridge Capital serving as the exclusive financial advisor.

This round of financing will further accelerate BrosMed Medical's pace in research and development innovation and market expansion, promoting the company to a higher level of development. The investors highly recognize BrosMed Medical's technical strength and market prospects in the medical device field, and look forward to deep cooperation between both parties in the healthcare sector in the future.

This round of financing is BrosMed Medical's follow-up2020YearCA new round of capital boost after the financing round. Public information shows that the company's registered capital has increased to5782.0355RMB, verifying its continuously growing capital value.

Wu Zhipeng from Star Bridge Capital stated:"We are very honored to assist BrosMed Medical in completing this round of financing. With an international strategic layout, excellent product performance, and efficient mass production capabilities, the company has achieved remarkable results in just a few years. We firmly believe that this financing will further consolidate the company's leading position in the industry and continue to lead industrial transformation and technological innovation."

Data shows that BrosMed Medical has advanced technical advantages and a research and development platform. It is the Guangdong Provincial Vascular Intervention Technology and Device Engineering Research Center, which consists of several chief scientists, national experts, and a high proportion of staff with postgraduate degrees or above.90%The team composition has accumulated rich experience in product development and process design. It owns several subsidiaries.

Among them,Shenzhen Bensun Medical Technology Co., Ltd. is a subsidiary of BrosMed Medical Co., Ltd., established in2020Year09Month03Located at No. X, Guanlan Street, Xinlan Community, Longhua District, Shenzhen City1301Silver Star Technology BuildingD906The company is mainly engaged in the research, development, and sales of active medical devices for prevention, treatment, and rehabilitation.

The company currently owns an area exceeding300The Pingmi R&D Center, which covers technology, information, testing and other R&D laboratories as well as R&D pilot workshops, has a staff consisting entirely of individuals with bachelor's degrees or higher, accounting for80%The above. And join hands with a high-quality R&D team in the industry to jointly build a high-tech R&D enterprise that integrates R&D, transformation, sales, and services. Currently, the company's products are in the registration stage.1Unit, Registered Product1Products currently under development have reached5.

Hunan BrosMed Medical Co., Ltd. is a manufacturing medical device enterprise formally registered in the Chuangye Innovation Park of Zhuzhou Yunlong Demonstration Zone, specializing in the research, development, production, sales, and service of high-end medical devices. The company is committed to achieving a competitive advantage for Chinese brands in the global high-end medical device consumables market by combining international product technologies and manufacturing process technologies owned by a team of top talents with the company's innovative and open business model. This approach aims to bring high returns to the company while driving the upgrading and growth of related industrial chains within China.

BrosMed MetaMed is a wholly-owned subsidiary of BrosMed Medical Co., Ltd., with a registered capital500Ten thousand yuan, established in2021Year4Month, located in Songshan Lake, Dongguan, Guangdong, with a factory area of1500Square meters. This is an important layout for BrosMed Medical in the field of neurointervention. BrosMed Yuentong Medical focuses on minimally invasive treatments in neurointervention, committed to creating a one-stop solution for stroke prevention and treatment. It boasts a full product pipeline, ranging from acute ischemic stroke and vascular stenosis treatment to hemorrhagic treatment and access devices.

BrosMed Medical has a dedicated R&D team whose members possess extensive experience in the research and development of catheters and stents. The educational backgrounds of the team members include materials, mechanical engineering, and medicine.70%The above refers to a postgraduate degree. Capable of designing and developing various types of catheters, stents, etc., based on customer needs.

BrosMed Medical is one of the largest balloon catheter manufacturers in China.15010,000 sets of balloon catheter production capacity,30010,000 sets of technical capacity. Annual catheter production capacity2010,000 sets, guidewire annual production capacity30Ten thousand sets. Yuentong Medical has sufficient production capacity by commissioning BrosMed Medical for manufacturing.

It is reported that,Cardiovascular diseases are one of the leading causes of death worldwide. With the aging population and changes in lifestyle, the demand for cardiovascular interventional devices continues to grow.

AndThe cardiovascular interventional device market includes a variety of products such as coronary stents, balloon dilation catheters, guidewires, occluders, and heart valves. These devices are mainly used for diagnosing and treating various cardiovascular diseases, such as coronary heart disease, arrhythmia, and congenital heart disease. In recent years, with technological advancements and product innovations, the cardiovascular interventional device market has shown a trend of rapid growth.

CurrentlyThe cardiovascular interventional device market is dominated by several well-known medical device companies, such as Medtronic (Medtronic), Boston Scientific (Boston Scientific), Abbott (Abbott Laboratories), etc. These companies, with their strong R&D capabilities and extensive market coverage, have occupied a dominant position in the market. Meanwhile, some emerging enterprises are gradually making a name for themselves through innovative products and technologies.